NKTR Valuation

Nektar Therapeutics

Add to Watchlist

Advanced Chart

22.990

-0.07(-0.304%)1D

Overview
Forecast
Valuation
Earnings

NKTR Relative Valuation

NKTR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NKTR is overvalued; if below, it's undervalued.

Historical Valuation

Nektar Therapeutics (NKTR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 9.86 is considered Overvalued compared with the five-year average of -2.96. The fair price of Nektar Therapeutics (NKTR) is between 4.59 to 15.33 according to relative valuation methord. Compared to the current price of 23.06 USD , Nektar Therapeutics is Overvalued By 50.43%.

Relative Value

Fair Zone

4.59-15.33

Current Price：23.06

50.43%

Overvalued

-2.02

Trailing

Forward

-2.59

EV/EBITDA

Nektar Therapeutics. (NKTR) has a current EV/EBITDA of -2.59. The 5-year average EV/EBITDA is -2.16. The thresholds are as follows: Strongly Undervalued below -6.68, Undervalued between -6.68 and -4.42, Fairly Valued between 0.11 and -4.42, Overvalued between 0.11 and 2.37, and Strongly Overvalued above 2.37. The current Forward EV/EBITDA of -2.59 falls within the Historic Trend Line -Fairly Valued range.

-2.44

EV/EBIT

Nektar Therapeutics. (NKTR) has a current EV/EBIT of -2.44. The 5-year average EV/EBIT is -1.96. The thresholds are as follows: Strongly Undervalued below -6.02, Undervalued between -6.02 and -3.99, Fairly Valued between 0.07 and -3.99, Overvalued between 0.07 and 2.10, and Strongly Overvalued above 2.10. The current Forward EV/EBIT of -2.44 falls within the Historic Trend Line -Fairly Valued range.

9.86

Nektar Therapeutics. (NKTR) has a current PS of 9.86. The 5-year average PS is 10.82. The thresholds are as follows: Strongly Undervalued below -11.05, Undervalued between -11.05 and -0.12, Fairly Valued between 21.76 and -0.12, Overvalued between 21.76 and 32.70, and Strongly Overvalued above 32.70. The current Forward PS of 9.86 falls within the Historic Trend Line -Fairly Valued range.

-2.16

P/OCF

Nektar Therapeutics. (NKTR) has a current P/OCF of -2.16. The 5-year average P/OCF is -3.91. The thresholds are as follows: Strongly Undervalued below -11.13, Undervalued between -11.13 and -7.52, Fairly Valued between -0.30 and -7.52, Overvalued between -0.30 and 3.31, and Strongly Overvalued above 3.31. The current Forward P/OCF of -2.16 falls within the Historic Trend Line -Fairly Valued range.

-2.06

P/FCF

Nektar Therapeutics. (NKTR) has a current P/FCF of -2.06. The 5-year average P/FCF is -4.91. The thresholds are as follows: Strongly Undervalued below -41.18, Undervalued between -41.18 and -23.04, Fairly Valued between 13.23 and -23.04, Overvalued between 13.23 and 31.36, and Strongly Overvalued above 31.36. The current Forward P/FCF of -2.06 falls within the Historic Trend Line -Fairly Valued range.

Nektar Therapeutics (NKTR) has a current Price-to-Book (P/B) ratio of 20.83. Compared to its 3-year average P/B ratio of 2.96 , the current P/B ratio is approximately 602.46% higher. Relative to its 5-year average P/B ratio of 2.90, the current P/B ratio is about 619.34% higher. Nektar Therapeutics (NKTR) has a Forward Free Cash Flow (FCF) yield of approximately -47.35%. Compared to its 3-year average FCF yield of -123.43%, the current FCF yield is approximately -61.64% lower. Relative to its 5-year average FCF yield of -82.13% , the current FCF yield is about -42.34% lower.

20.83

P/B

Median3y

2.96

Median5y

2.90

-47.35

FCF Yield

Median3y

-123.43

Median5y

-82.13

Competitors Valuation Multiple

The average P/S ratio for NKTR's competitors is 11.06, providing a benchmark for relative valuation. Nektar Therapeutics Corp (NKTR) exhibits a P/S ratio of 9.86, which is -10.87% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Lexicon Pharmaceuticals Inc

CytomX Therapeutics Inc

4.84

-25.71%

387.55M

Performance Decomposition

Market capitalization of NKTR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of NKTR in the past 1 year is driven by Unknown.